Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | OGG1 | O15527 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoquinone SCHEMBL28257947 | 0.91 | PDE2A (0.44) | PDE2AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL10921467 | 0.89 | SSTR4 (0.43) | PDE2AKMT2ANPC1RAB9AHDAC1 | |
| SCHEMBL22938368 | 0.85 | PDE2A (0.44) | PDE2AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL165889 | 0.84 | ACACB (0.48) | PDE2AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL8446830 | 0.83 | NPC1 (0.48) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL22772342 | 0.82 | ESR1 (0.48) | MEN1KMT2ALMNASSTR4ALDH1A1 | |
| SCHEMBL935057 | 0.81 | SSTR4 (0.53) | KMT2AHDAC1CYP1A2CYP2C19SSTR4 | |
| SCHEMBL3801424 | 0.81 | MEN1 (0.43) | PDE2AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL529254 | 0.80 | EPHX2 (0.42) | PDE2AMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2884007 | 0.80 | TPMT (0.40) | PDE2ANPC1RAB9AHDAC1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| EP-3267983-B1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORP (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| EP-4165045-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | Monash University (AU) | 2023-04-19 | — | — | EP | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2011068899-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-1222175-B1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | CELLTECH R&D LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2005-08-04 | — | — | US | disclosed |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2004-11-25 | — | — | US | disclosed |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | DAVIS JEREMY MARTIN (GB) | 2003-11-13 | — | — | US | disclosed |
| US-6600037-B1 | The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis. | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
| EP-1222175-A1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | Celltech R&D Limited (GB) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001029009-A1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | CELLTECH R&D LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PDE2A 4453/4885MEN1 1644/4885KMT2A 968/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | PDE2A 951/4885MEN1 3277/4885KMT2A 4465/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PDE2A 4453/4885MEN1 1644/4885KMT2A 968/4885 |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | NFKBIA, IKBKB, IKBKG | PDE2A 3618/4885MEN1 3778/4885KMT2A 823/4885 |
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FLT4, FGFR1 | PDE2A 3567/4885MEN1 4308/4885KMT2A 2555/4885 |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | PDE2A 4114/4885MEN1 4696/4885KMT2A 2092/4885 |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | PDE2A 3444/4885MEN1 2118/4885KMT2A 636/4885 |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | PDE2A 4130/4885MEN1 4699/4885KMT2A 2109/4885 |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | TLR1, TLR3, TLR9 | PDE2A 714/4885MEN1 4078/4885KMT2A 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.